Seegene

The company's new QuantStudio 5 Dx Real-Time PCR system allows users to wield multi-modal software to detect pathogens.

The agreement with Mexico's agriculture department covers studies to evaluate molecular detection assays for bovine TB, as well as studies on zoonotic TB diagnosis.

The partnership marks the first step in the company's plan to develop 100 new molecular diagnostics within the next two years.

Seegene will use its proprietary assay development technologies to create highly multiplexed tests for the Hologic Fusion platform. 

Partnering with Biodist Group, the South Korean molecular diagnostics firm is looking to move into non-human applications such as food safety testing.

The worldwide collaboration agreement is for co-development of multiplex real-time PCR reagents for the BD Max molecular diagnostics platform.

Seegene will develop a menu of multiplex assay panels, initally in the area of infectious disease, for Qiagen's QIAsymphony RGQ molecular diagnostics platform.

The company has also received approvals for various molecular diagnostics in the US and Canada in recent months.

The South Korean molecular diagnostics firm plans to grow its global market presence and pursue FDA approval for its products from Seegene Technologies, its new base in California.